Persistence of an infectious form of SARS-CoV-2 post protease inhibitor treatment of permissive cells in vitro
Description
Reports have described SARS-CoV-2 rebound in COVID-19 patients treated with nirmatrelvir, a 3CL protease inhibitor. The cause remains a mystery, although drug resistance, re-infection, and lack of adequate immune responses have been excluded. We now
